恶唑烷酮类化合物依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）与万古霉素相比，对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
作者信息
Rybak M J, Cappelletty D M, Moldovan T, Aeschlimann J R, Kaatz G W
机构信息
The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, Wayne State University, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
Abstract
The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus (n = 200), coagulase-negative staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium (n = 50). Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 microg/ml) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 microg/ml). In time-kill studies, eperezolid and linezolid were bacteriostatic in action. A postantibiotic effect of 0.8+/-0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.
摘要
将恶唑烷酮类抗菌剂依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）的活性与万古霉素针对甲氧西林敏感和耐药金黄色葡萄球菌（n = 200）、凝固酶阴性葡萄球菌（n = 100）以及万古霉素敏感和耐药粪肠球菌及屎肠球菌（n = 50）的临床分离株进行了比较。无论葡萄球菌对甲氧西林的敏感性（抑制90%分离株的最低抑菌浓度[MIC90]范围为1至4微克/毫升）或肠球菌对万古霉素的敏感性（MIC90范围为1至4微克/毫升）如何，依哌唑胺和利奈唑胺均表现出良好的体外抑制活性。在时间杀菌研究中，依哌唑胺和利奈唑胺具有抑菌作用。依哌唑胺和利奈唑胺对金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌和屎肠球菌均表现出0.8±0.5小时的抗生素后效应。
相似文献
1
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.恶唑烷酮类化合物依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）与万古霉素相比，对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
2
Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.利奈唑胺对意大利分离的葡萄球菌和肠球菌的比较活性。
Clin Microbiol Infect. 2002 Jun;8(6):368-72. doi: 10.1046/j.1469-0691.2002.00429.x.
3
Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.恶唑烷酮类药物利奈唑胺和依哌唑胺在粪肠球菌或耐万古霉素屎肠球菌所致实验性腹腔内脓肿中的活性。
Antimicrob Agents Chemother. 1999 Dec;43(12):2873-6. doi: 10.1128/AAC.43.12.2873.
4
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.达托霉素、利奈唑胺和奎奴普丁-达福普汀对包括万古霉素中介金黄色葡萄球菌和万古霉素耐药粪肠球菌在内的葡萄球菌和肠球菌挑战组的体外活性。
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
5
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.评价替加环素对金黄色葡萄球菌和对万古霉素、达托霉素或利奈唑胺敏感性降低的肠球菌的抗菌活性。
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
6
In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.恶唑烷酮类药物RWJ-416457对耐利奈唑胺和对利奈唑胺敏感的葡萄球菌及肠球菌的体外活性
Antimicrob Agents Chemother. 2007 Mar;51(3):1112-4. doi: 10.1128/AAC.01347-06. Epub 2007 Jan 8.
7
Novel tetrahydro-thieno pyridyl oxazolidinone: an antibacterial agent.新型四氢噻吩并吡啶基恶唑烷酮：一种抗菌剂。
Bioorg Med Chem. 2004 Sep 1;12(17):4557-64. doi: 10.1016/j.bmc.2004.07.019.
8
A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.金黄色葡萄球菌和肠球菌属暴露于替考拉宁、万古霉素、利奈唑胺和奎奴普丁-达福普汀后耐药性选择的体外比较评估
Clin Microbiol Infect. 2008 Jun;14(6):608-11. doi: 10.1111/j.1469-0691.2008.01993.x. Epub 2008 Apr 5.
9
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.利奈唑胺联合其他抗菌药物对葡萄球菌、肠球菌、肺炎球菌及部分革兰阴性菌的体外活性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1902-6. doi: 10.1128/AAC.47.6.1902-1906.2003.
10
Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.利奈唑胺对革兰氏阳性菌的抗生素后生长抑制作用。
J Antimicrob Chemother. 2001 Jun;47(6):879-83. doi: 10.1093/jac/47.6.879.
引用本文的文献
1
Difficult-to-Treat Pathogens: A Review on the Management of Multidrug-Resistant .难治疗病原体：关于多重耐药菌管理的综述
Life (Basel). 2023 May 4;13(5):1126. doi: 10.3390/life13051126.
2
Methicillin-Resistant (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence Factors, Antibiotic-Resistance, and Zoonotic Impact.耐甲氧西林金黄色葡萄球菌（MRSA）：从“同一健康”视角看该细菌的流行病学、毒力因子、抗生素耐药性及人畜共患病影响
Infect Drug Resist. 2020 Sep 22;13:3255-3265. doi: 10.2147/IDR.S272733. eCollection 2020.
3
Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.《恶唑烷酮类的临床药代动力学与药效动力学》
Clin Pharmacokinet. 2018 May;57(5):559-575. doi: 10.1007/s40262-017-0601-x.
4
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.特拉万星：一种新型半合成脂糖肽类药物，用于应对耐革兰氏阳性病原体的挑战。
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
5
Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.单时间点策略预测患者利奈唑胺血药浓度曲线下面积的适用性：谷浓度与峰浓度衍生线性回归模型的优越性
Drugs R D. 2016 Mar;16(1):69-79. doi: 10.1007/s40268-015-0117-5.
6
Coagulase-negative staphylococci.凝固酶阴性葡萄球菌
Clin Microbiol Rev. 2014 Oct;27(4):870-926. doi: 10.1128/CMR.00109-13.
7
Local release of antibiotics for surgical site infection management using high-purity calcium sulfate: an in vitro elution study.使用高纯度硫酸钙进行手术部位感染管理的抗生素局部释放：一项体外洗脱研究。
Surg Infect (Larchmt). 2015 Feb;16(1):54-61. doi: 10.1089/sur.2013.162. Epub 2014 Aug 22.
8
Alternative strategies for proof-of-principle studies of antibacterial agents.抗菌剂原理验证研究的替代策略。
Antimicrob Agents Chemother. 2014 Aug;58(8):4257-63. doi: 10.1128/AAC.02473-14. Epub 2014 May 27.
9
Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.利奈唑胺与万古霉素预防大鼠耐甲氧西林金黄色葡萄球菌或表皮葡萄球菌血管移植物感染的比较：一项随机对照实验研究。
Curr Ther Res Clin Exp. 2007 Jan;68(1):23-31. doi: 10.1016/j.curtheres.2007.02.001.
10
Clinical update on linezolid in the treatment of Gram-positive bacterial infections.利奈唑胺治疗革兰氏阳性菌感染的临床最新进展。
Infect Drug Resist. 2012;5:87-102. doi: 10.2147/IDR.S25890. Epub 2012 Jun 25.
本文引用的文献
1
In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.两种新型恶唑烷酮类药物（U100592和U100766）、一种新型氟喹诺酮类药物（曲伐沙星）以及达福普汀-奎奴普汀对金黄色葡萄球菌和表皮葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2428-30. doi: 10.1128/AAC.40.10.2428.
2
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.恶唑烷酮类化合物U100592和U100766对金黄色葡萄球菌和表皮葡萄球菌的体外活性
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
3
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
4
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
5
In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.新型恶唑烷酮类抗菌剂U - 100592和U - 100766对实验性细菌感染的体内活性
Antimicrob Agents Chemother. 1996 Jun;40(6):1508-13. doi: 10.1128/AAC.40.6.1508.
6
Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.在体外心内膜炎药效学模型中，替考拉宁、万古霉素和庆大霉素单独及联合使用对金黄色葡萄球菌的杀菌活性。
Antimicrob Agents Chemother. 1994 Sep;38(9):2034-40. doi: 10.1128/AAC.38.9.2034.
7
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.恶唑烷酮类，一类新型合成抗菌剂：DuP 105和DuP 721的体外及体内活性
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.
8
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.新型恶唑烷酮化合物DuP 105和DuP 721的活性及作用机制
J Antimicrob Chemother. 1988 Jun;21(6):721-30. doi: 10.1093/jac/21.6.721.
9
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.两种恶唑烷酮类抗菌剂DuP 721和DuP 105的体外活性
Antimicrob Agents Chemother. 1988 Apr;32(4):580-3. doi: 10.1128/AAC.32.4.580.
10
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.新型恶唑烷酮类抗菌剂DuP 105和DuP 721的体外评价
Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.
Zotero 插件